Citadel Advisors
BBIO icon

Citadel Advisors’s BridgeBio Pharma BBIO Stock Holding History

Citadel Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.06M Sell
54,700
-56,700
-51% -$4.11M ﹤0.01% 4689
2025
Q4 		$8.52M Sell
111,400
-16,200
-13% -$1.06M ﹤0.01% 3470
2025
Q3 		$6.63M Sell
127,600
-52,700
-29% -$2.57M ﹤0.01% 3871
2025
Q2 		$7.79M Sell
180,300
-48,300
-21% -$1.76M ﹤0.01% 3397
2025
Q1 		$7.9M Sell
228,600
-71,400
-24% -$2.41M ﹤0.01% 3182
2024
Q4 		$8.23M Buy
300,000
+70,600
+31% +$1.82M ﹤0.01% 3232
2024
Q3 		$5.84M Buy
229,400
+23,300
+11% +$612K ﹤0.01% 3703
2024
Q2 		$5.22M Buy
206,100
+107,600
+109% +$2.94M ﹤0.01% 3686
2024
Q1 		$3.05M Buy
98,500
+17,000
+21% +$578K ﹤0.01% 4764
2023
Q4 		$3.29M Sell
81,500
-47,400
-37% -$1.42M ﹤0.01% 4499
2023
Q3 		$3.4M Sell
128,900
-166,900
-56% -$4.74M ﹤0.01% 4274
2023
Q2 		$5.09M Buy
295,800
+17,000
+6% +$256K ﹤0.01% 3615
2023
Q1 		$4.62M Buy
278,800
+264,300
+1,823% +$3.08M ﹤0.01% 3948
2022
Q4 		$110K Sell
14,500
-29,500
-67% -$282K ﹤0.01% 11081
2022
Q3 		$437K Sell
44,000
-5,500
-11% -$57.1K ﹤0.01% 8759
2022
Q2 		$449K Sell
49,500
-28,600
-37% -$239K ﹤0.01% 8879
2022
Q1 		$793K Sell
78,100
-213,700
-73% -$2.19M ﹤0.01% 8241
2021
Q4 		$4.87M Buy
291,800
+198,400
+212% +$8.39M ﹤0.01% 4335
2021
Q3 		$4.38M Buy
93,400
+8,900
+11% +$477K ﹤0.01% 4562
2021
Q2 		$5.15M Buy
84,500
+2,400
+3% +$137K ﹤0.01% 4356
2021
Q1 		$5.06M Buy
+82,100
New +$5.37M ﹤0.01% 4236
2020
Q4 		– Sell
-7,200
Closed -$270K – 10896
2020
Q3 		$270K Buy
+7,200
New +$227K ﹤0.01% 8309

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's BBIO Position: Q1 2026 in Review

Citadel Advisors increased its BridgeBio Pharma (BBIO) stake by 355% in Q1 2026, buying an estimated $179M and bringing the position to 3,173,940 shares worth $236M. The position accounts for 0.04% of the portfolio, ranked #387.

Citadel Advisors first reported a position in BBIO in Q2 2019 and has held it in 24 quarters since. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Citadel Advisors held 3,173,940 shares of BridgeBio Pharma worth $236M as of Q1 2026.
  • Citadel Advisors bought 2,475,758 BridgeBio Pharma shares in Q1 2026, an estimated $179M.
  • BridgeBio Pharma made up 0.04% of Citadel Advisors's portfolio in Q1 2026, its #387 holding.
  • Citadel Advisors first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 24 quarters since.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.